ASCO: Dabrafenib/Trametinib Active in Metastatic Melanoma
(HealthDay News) – For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic melanoma, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1–5 in Chicago.
Jeffrey S. Weber, MD, MPH, from the H. Lee Moffitt Cancer Center in Tampa, FL, and colleagues enrolled 125 patients with V600 BRAF-mutant solid tumors, including 77 patients with metastatic melanoma who had not received prior treatment with BRAF inhibitors. Patients were treated at four escalating dose levels of 75/1, 150/1, 150/1.5, and 150/2 (mg twice daily/mg once daily) of dabrafenib/trametinib, and safety and efficacy were assessed.
The researchers found that the overall response rate was 56% among the 77 melanoma patients. At ascending dose levels, the confirmed response rate was 67%, 64%, 48%, and 54%, respectively. The overall progression-free survival (PFS) was 7.4 months. For the corresponding dose levels, the median PFS was 8.7, 8.3, and 5.5 months, with PFS not mature for the 150/2 dose level. Among the cohort of 125 patients, there were two Grade 5 adverse events, pneumonia and hyponatremia; the most common Grade 3/4 adverse events were pyrexia, fatigue, and dehydration. Grade 2 or higher skin toxicity was seen in 14% of patients. Cutaneous squamous cell carcinoma and actinic keratoses each occurred in 2% of patients.
"It's fascinating to find such promising effects with this combination regimen. Not only are the two drugs causing shrinkage of the cancer, but we're seeing that a second anti-cancer therapy may actually suppress the side effects of the first," Weber said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures dabrafenib/trametinib.